Dainippon to acquire $2.5bn Boston Biomedical as a global oncology base
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) is to acquire privately-held biotech firm Boston Biomedical (BBI) for $200 million up front and a further $2.43 billion in development and sales milestones. DSP said it intends to use BBI to establish a global oncology R&D base in the US.